Dr Montagnier VIH
Immunotec congratulates 2008 Nobel Prize Winner in Medicine, Dr. Luc Montagnier, Montreal, Quebec, Canada, October 23, 2008
Immunotec Inc. (TSX-V IMM) congratulates Dr. Luc Montagnier for winning the 2008 Nobel Prize in Medicine for his 1984 discovery, with Françoise Barré-Sinoussi, of the human immunodeficiency virus (HIV). Drs. Montagnier and Barré-Sinoussi first understood that HIV “impaired the immune system because of massive virus replication and cell damage to lymphocytes.” Their seminal work set the stage for understanding of the biology of the disease and current modalities of treatment. In addition, it led to development of methods of diagnosis and blood screening that has mitigated the spread of the disease. In related work, Immunotec Senior Vice-President, Research & Development, Dr. Wulf Dröge and his colleagues were the first to discover (in 1989) that HIV-infected patients have abnormally low cysteine and glutathione levels. In 1994, Montagnier drew attention to the promising effects of Immunotec’s cornerstone product, Immunocal®, a proven precursor of the major cellular antioxidant glutathione, in his opening address at the 10th International AIDS Conference in Yokohama, Japan. The anti-HIV and anti-apoptotic activity of Immunocal and its relation with GSH synthesis were further discussed in a presentation at the same conference. Three years later, Montagnier, Olivier and Catherine Pasquier edited Oxidative Stress in Cancer, AIDS, and Neurodegenerative Diseases, devoting an entire chapter to a paper co-authored by Immunotec founding scientist Dr. Gustavo Bounous. Entitled Nutriceutical Modulation of Glutathione with a Humanized Native Milk Serum Protein Isolate, Immunocal: Application in AIDS and Cancer, the paper explored the extremely rare glutathione-promoting components of proteins in Immunocal and noted the implication of cellular glutathione depletion in a number of degenerative conditions and disease states including Parkinson’s, Alzheimer’s, arteriosclerosis, cataracts, cystic fibrosis, malnutrition, aging, AIDS, and cancer. Immunotec salutes the achievements of Dr. Luc Montagnier. The collaboration of science and medicine in quickly understanding and providing treatment for infected individuals has led to significant improvement in life expectancies for those infected and resonates with Immunotec’s mission of helping human beings achieve wellness. About Immunocal Immunocal is a cysteine-rich protein isolate derived from non-denatured whey protein. Immunocal® is a dietary natural health supplement, developed and marketed worldwide by Immunotec since 1996. Immunocal® is a precursor of the major cellular antioxidant glutathione, an element important in maintaining a strong immune system. About Immunotec Inc. Immunotec is engaged primarily in the development and marketing of natural health products, dietary supplements, vitamins and personal care products, many of which are manufactured on its behalf by third parties. Immunotec’s products are distributed and sold in the United States and Canada through a network marketing system and in other countries through exclusive distributorship agreements. Immunotec’s investment in this study is another manifestation of its ongoing commitment to research and development. www.immunotec.com.
John H. Molson, Vice-President, Research & Development Immunotec Inc.
300 Joseph Carrier, Vaudreuil-Dorion, QC, J7V 5V5
Tel: 450 510-4450 Fax: 450 424-9993
Clare Malbon, R&D Dept. 450 424-9992 Ext 2377
- Discovery of the health benefits of Immunocal
- Medicare/Medicaid in the U.S.
- Which illnesses may be affected by raising glutathione?
- As listed in the Physicians’ Desk Reference (PDR)
- What is Glutathione?
- What is Immunocal?
- Athletic Performance and Immunocal
- Effect of supplementation with a cysteine donor
- Dr Montagnier VIH
- Dr Montagnier
- NSU and Immunotec Start Clinical Trial in Autism
- Stress Oxidatif Cancer, SIDA, et Maladies Neurodégénératives
- IMMUNOTEC MEDICAL PUBLICATIONS
- IMMUNOTEC MEDICAL PUBLICATIONS 2